CMT2A is a dominant neuropathy in which patients are heterozygous for MFN2 mutations, but it is not known whether the CMT2A phenotype results from MFN2 haploinsufficiency is a dominant negative effect on the WT allele or is semi-dominant. This evidence concerns the gene MFN2 and neuropathy.